21,884 Shares in AtriCure, Inc. (NASDAQ:ATRC) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 21,884 shares of the medical device company's stock, valued at approximately $614,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI bought a new position in shares of AtriCure during the third quarter valued at about $28,000. Comerica Bank raised its position in AtriCure by 70.5% during the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company's stock valued at $77,000 after purchasing an additional 1,043 shares during the last quarter. nVerses Capital LLC lifted its holdings in AtriCure by 733.3% in the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company's stock worth $140,000 after buying an additional 4,400 shares during the period. Quest Partners LLC grew its position in shares of AtriCure by 38.3% in the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock worth $134,000 after buying an additional 1,626 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of AtriCure during the third quarter valued at approximately $230,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Down 3.4 %

AtriCure stock traded down $1.12 during trading hours on Friday, hitting $31.67. The stock had a trading volume of 494,255 shares, compared to its average volume of 699,184. The stock's 50-day moving average price is $32.93 and its 200-day moving average price is $27.25. The stock has a market capitalization of $1.54 billion, a P/E ratio of -38.16 and a beta of 1.40. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $39.04. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The business had revenue of $115.91 million for the quarter, compared to the consensus estimate of $112.23 million. During the same period last year, the business posted ($0.20) EPS. The company's revenue was up 17.9% compared to the same quarter last year. Equities research analysts anticipate that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Ratings Changes

ATRC has been the topic of several recent analyst reports. Needham & Company LLC lifted their price target on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Canaccord Genuity Group raised their target price on shares of AtriCure from $53.00 to $61.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Oppenheimer boosted their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on shares of AtriCure from $30.00 to $40.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Finally, UBS Group upped their target price on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and an average price target of $42.00.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.